Company code: Star Lake Bioscience Co.Inc.Zhaoqing Guangdong(600866) company abbreviation: Star Lake Bioscience Co.Inc.Zhaoqing Guangdong(600866) Star Lake Bioscience Co.Inc.Zhaoqing Guangdong(600866)
Summary of annual report 2021
Section I important tips
1 the summary of this annual report comes from the full text of the annual report. In order to fully understand the company’s operating results, financial status and future development plan, investors should go to www.sse.com com. cn. The website carefully reads the full text of the annual report. 2. The board of directors, the board of supervisors and the directors, supervisors and senior managers of the company guarantee the authenticity, accuracy and completeness of the contents of the annual report, and there are no false records, misleading statements or major omissions, and bear individual and joint legal liabilities. 3. All directors of the company attend the board meeting. 4 ShineWing Certified Public Accountants (special general partnership) issued a standard unqualified audit report for the company. 5. The profit distribution plan or the plan of converting accumulation fund into share capital in the reporting period adopted by the resolution of the board of directors
As the company’s accumulated profit available for distribution to shareholders in 2021 is still negative, it does not meet the cash dividend conditions specified in the articles of association and dividend management system of the company. At the same time, considering the large capital demand of the company’s technical transformation projects and operating expenses in 2022, combined with the actual situation of the company’s production and operation, it is planned not to carry out profit distribution and convert the accumulation fund into share capital in 2021.
The above distribution plan has been deliberated and approved at the 15th meeting of the 10th board of directors held on March 25, 2022, and needs to be submitted to the general meeting of shareholders for deliberation.
Section II basic information of the company
1 company profile
Company stock profile
Stock type stock exchange stock abbreviation stock abbreviation before stock code change
A-share Shanghai Stock Exchange Star Lake Bioscience Co.Inc.Zhaoqing Guangdong(600866) Star Lake Bioscience Co.Inc.Zhaoqing Guangdong(600866) not applicable
Contact person and contact information secretary of the board of directors securities affairs representative
Name: Liu Xinxin, Zhang Kaijia
Office address: No. 67, Gongnong North Road, Zhaoqing City, Guangdong Province
Tel: 075822911 Anshan Hifichem Co.Ltd(300758) 2237526
E-mail [email protected]. [email protected].
2. Introduction to the company’s main business in the reporting period
(I) food additive industry:
Food additives are widely used in food processing. They play an important role in food preservation and improving food nutritional value. They are indispensable and important raw materials for modern food industry. Food additives meet the escalating consumer demand of the people and make important contributions to the prosperity and development of the food industry.
In the food additive industry chain, the upstream is food additive raw materials, which are mainly divided into green natural ingredients and fine chemical raw materials. The midstream is the manufacturer of various food additives, and the downstream is widely used in various foods, beverages and condiments. In the process of the rapid development of the food additive industry, with the increasing attention of the society to food safety and the increasing supervision of the state on enterprise environmental protection, some small-scale and non-standard enterprises will be gradually eliminated, the development of advantageous enterprises will be more rapid, the industry integration will be further accelerated, the market concentration will be continuously improved, and the large-scale operation of enterprises has become the inevitable trend of the development of the industry.
The company has first mover advantages and technical advantages in food additives. It is the first to develop, produce and sell nucleotide additive products in China. The company’s research and development of flavored disodium nucleotide is a national torch plan project. The research and development results were products that filled the gap in China at that time and won the second prize of national scientific and technological progress award. The main products of the company’s food additives are: Xinghu brand food additives series – flavored disodium nucleotide (I plus g), disodium inosinic acid (IMP), corn fermented products and so on. In 2021, the company’s sales revenue of food additives was 768 million yuan, with a year-on-year increase of 10.33%, accounting for 62.94% of the operating revenue.
(II) chemical API and intermediate industry:
Chemical APIs are located in the upstream of the pharmaceutical industry chain and are the basis for ensuring drug supply and meeting the drug demand of Chinese residents. Pharmaceutical intermediate is a fine chemical product in the production process from pharmaceutical chemical raw materials to API or drugs. The synthesis of chemical drugs depends on high-quality pharmaceutical intermediates. The downstream industry of the pharmaceutical intermediate industry is mainly the API production industry, and the API and preparation are in the relationship between the upstream and downstream industrial chain. The consumption demand of downstream preparation drugs will directly affect the demand of API. With the improvement of people’s living standards, the degree of aging is rising, and the demand for drugs is on the rise for a long time. Therefore, the development from finished drugs to the whole intermediate and API industry. In recent years, affected by the sharp decline in the output of API, the price of API has an obvious upward trend, which has raised the production cost of downstream chemical pharmaceutical enterprises. Pharmaceutical enterprises have successively formed the upstream and downstream docking of the pharmaceutical industry chain through self built API production lines or mergers and acquisitions of API production enterprises, increasing the competition of China’s API industry. On November 9, 2021, the national development and Reform Commission and the Ministry of industry and information technology jointly issued the notice on the implementation plan for promoting the high-quality development of API industry, which repeatedly emphasized the green and low-carbon direction, supporting equipment and consumables and the development of industrial clusters. China’s API industrial structure will be more reasonable, the proportion of API produced by green process will be further increased, and small and medium-sized production capacity will be gradually eliminated to improve the industry concentration.
The company also has core technologies in biological fermentation and chemical synthesis, and has technical and production advantages in biochemical APIs and pharmaceutical intermediates. The main products of the company’s chemical raw materials and intermediates are: Yue Bao brand medicine series – inosine, Leigh Bhave Lin, proline, guanosine, adenosine, adenine, intermediate of AIDS, hepatitis C drug intermediates, diabetes drug intermediates, analgesic intermediates, cardiovascular drug intermediate, cancer drug intermediates, etc. In 2021, the company’s sales revenue of chemical APIs and intermediates was 453 million yuan, with a year-on-year increase of 10.46%, accounting for 37.06% of the operating revenue.
(I) main business conditions
Focusing on biological fermentation and chemical synthesis as the core technology, the company is mainly engaged in the R & D, production and sales of food additives, pharmaceutical intermediates and chemical APIs and preparations. The application scope of products covers many fields such as food processing and pharmaceutical manufacturing. The company’s main production bases are located in Zhaoqing City, Guangdong Province, Suihua City, Heilongjiang Province, Yibin and Guang’an City, Sichuan Province.
(II) business model
Compared with previous years, there was no significant change in the company’s business model during the reporting period. The company mainly adopts large-scale production mode, reasonable inventory of products, production based on sales and production and sales balance. The company formulates annual and monthly production plans according to the sales demand plan or customer order plan. Each production plant plans production according to the mode of sales and production promotion.
The main raw (combustion) materials used in the production process of the company are corn starch, coal and natural gas. The procurement mode is mainly bidding procurement. The main or key raw materials used in production are directly purchased from the manufacturer, and some purchased energy is purchased from the local power supply department and the third party.
The company will negotiate directly with customers on the basis of product quality and market demand, and directly negotiate with customers on the basis of the company’s product quality and other factors.
3 main accounting data and financial indicators of the company 3.1 main accounting data and financial indicators in recent three years
Unit: yuan currency: RMB
20212020 compared with 2019 of the previous year
Increase or decrease (%)
Total assets 247334931272242196929810 2.12211623240216
Attributable to listed companies
Net assets of shareholders of the company 177560757886166899503126 6.39152028476723
Operating income 123504685804111627726822 10.64104960953113
Attributable to listed companies
The net profit of shareholders of the company 1064698807014871026403 – 28.4014955236809 belongs to the listed company
The net profit of the company’s shareholders deducting 967875057012649919565 -23.4914459218845 non recurring profits and losses is generated from operating activities
Net cash flow of 1926290978724998572949 -22.9421316911799
Weighted average net assets 6.18 9.33 decreased by 3.15% and 11.08 yield (%) points
Basic earnings per share 0.1441 0.2012 -28.38 0.2024 (yuan / share)
Diluted earnings per share 0.1441 0.2012 -28.38 0.2024 (yuan / share) 3.2 main accounting data by quarter in the reporting period
Unit: yuan currency: RMB
First quarter second quarter third quarter fourth quarter (January March) (April June) (July September) (October December) operating revenue 30403533729277013559542438347472941016321392
346108190241415765753571198482687209745 net profit attributable to shareholders of listed company
Net profit after deducting non recurring profit and loss: 313909292139771436991097747162452739234
Cash flow from operating activities 1412000943 -810222164623018149212430949516 net
Description of differences between quarterly data and disclosed periodic report data □ applicable √ not applicable 4 shareholders 4.1 total number of ordinary shareholders, total number of preferred shareholders with voting rights restored, total number of shareholders holding special voting shares and top 10 shareholders at the end of the reporting period and the end of the month before the disclosure of the annual report
Unit: shares
As of the end of the reporting period, the total number of common shareholders (households) was 54801
Total number of ordinary shareholders (households) at the end of last month before the disclosure date of annual report: 50802
As of the end of the reporting period, the total number of preferred shareholders (households) whose voting rights have been restored is not applicable
The total number of preferred shareholders (households) whose voting rights were restored at the end of the previous month before the disclosure date of the annual report is not applicable
Shareholding of top 10 shareholders
